Core Viewpoint - BriaCell Therapeutics Corp. has announced a public offering of 5,366,726 units at a price of $5.59 per unit, aiming to raise approximately $30 million before expenses [1][2]. Group 1: Offering Details - Each unit consists of one common share (or a pre-funded warrant) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" [1]. - The warrants are immediately exercisable at an exercise price of $6.93 per share and will expire five years from issuance [1]. - The offering is expected to close on January 15, 2026, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for working capital requirements, general corporate purposes, and advancing the company's business objectives [3]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [4]. - The offering is being made only by means of a prospectus, with copies available from ThinkEquity [4]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6].

Core Viewpoint - Hallador Energy Company plans to offer and sell $50 million of its common stock in an underwritten public offering, with a potential additional 15% option for underwriters [1] Group 1: Offering Details - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1] - Hallador intends to use the net proceeds for general corporate purposes, including funding initial financial commitments for a new natural gas generating facility [2] - Texas Capital Securities is the sole bookrunner, while Northland Capital Markets is acting as co-manager for the offering [2] Group 2: Registration and Prospectus - The securities are being offered under an automatic shelf registration statement on Form S-3, effective upon filing with the SEC on January 13, 2026 [3] - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus supplement will also be filed [4] Group 3: Company Overview - Hallador Energy Company is a vertically-integrated Independent Power Producer based in Terre Haute, Indiana, with two core businesses: Hallador Power Company, which operates the Merom Generating Station, and Sunrise Coal, which supplies fuel [6]

Core Viewpoint - Signing Day Sports, Inc. has announced a public offering of 9,483,500 shares of common stock at a price of $0.5905 per share, along with warrants to purchase an additional 14,225,250 shares [1][3] Group 1: Offering Details - The warrants will be initially exercisable at $0.7086 per share and can be exercised on a zero cash basis, subject to a floor price of $0.6760 per share until January 26, 2026 [2] - The gross proceeds from the offering are expected to be $5.6 million before deducting underwriting discounts and commissions [3] - The offering is expected to close on January 14, 2026, pending customary closing conditions [3] Group 2: Company Background - Signing Day Sports aims to assist student-athletes in the recruitment process for college sports through its app, which allows users to create recruitment profiles with video-verified measurables and academic information [6]

Group 1 - Phathom Pharmaceuticals, Inc. announced a public offering of 6,875,000 shares of common stock priced at $16.00 per share, along with pre-funded warrants for 1,250,078 shares priced at $15.999 each, aiming for gross proceeds of approximately $130 million before expenses [1][2] - The offering is expected to close on or about January 9, 2026, pending customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 1,218,761 shares at the public offering price [1] Group 2 - The net proceeds from the offering will be used for general corporate purposes, including working capital and expenses related to commercialization and research and development [2] - Guggenheim Securities and Cantor are acting as joint bookrunning managers, with Raymond James, Needham & Company, H.C. Wainwright & Co., and Craig-Hallum serving as co-managers for the offering [2] Group 3 - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases, including the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker [5] - Vonoprazan is marketed in the U.S. under the brand name VOQUEZNA® for various gastrointestinal conditions, including heartburn and H. pylori infection [5]

Company Overview - Triton International Limited is the world's largest lessor of intermodal freight containers, with a fleet exceeding 7 million twenty-foot equivalent units (TEU) of owned and managed containers [8]. Offering Details - The company announced the pricing of an underwritten offering of 7,000,000 Series G Cumulative Redeemable Perpetual Preference Shares at a liquidation preference of $25.00 per share, resulting in gross proceeds of $175,000,000 [1]. - The net proceeds from the offering will be used for general corporate purposes, including the purchase of containers, payment of dividends, and repayment or repurchase of outstanding indebtedness [2]. - The offering is expected to close on January 12, 2026, subject to customary closing conditions, and the Series G Preference Shares will be listed on the New York Stock Exchange under the symbol "TRTN PRG" [2]. Management and Underwriters - Wells Fargo Securities, LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, and UBS Investment Bank are acting as joint book-running managers for the offering, while Brookfield Capital Solutions, Huntington Securities, Inc., and Regions Securities LLC are co-managers [2].

Core Viewpoint - Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants to raise between $12 million and $15 million for regulatory clearance and market release of its Novasight Hybrid system, along with working capital needs [2][3][6]. Group 1: Offering Details - The offering consists of a minimum of 26,666,667 and a maximum of 33,333,333 securities priced at $0.45 per common share or $0.44999 per pre-funded warrant [2]. - Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.00001, with no expiration and can be exercised on a cashless basis [2]. - The offering may be completed in one or more tranches, with an expected initial closing date around January 13, 2026, subject to regulatory approvals [6]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to obtain US FDA 510(k) clearance for the Novasight Hybrid system and to facilitate a targeted market release in the United States [3]. - Additional proceeds will be allocated for working capital and general corporate purposes [3]. Group 3: Agent and Fees - The company will pay the agent, Bloom Burton Securities Inc., a cash fee of 6.5% of the gross proceeds and grant compensation options equal to 6.5% of the total number of securities issued [7]. - A reduced cash commission of 3.25% will apply for certain purchasers on a president's list, with no compensation options for those sales [7]. Group 4: Regulatory Filings - An amended and restated final short form prospectus was filed on January 7, 2026, with securities regulatory authorities in Alberta, British Columbia, and Ontario [5]. - The offering is subject to customary closing conditions, including necessary regulatory and stock exchange approvals [6]. Group 5: Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [12]. - The Novasight Hybrid system combines intravascular ultrasound and optical coherence tomography into a single device, enabling simultaneous imaging of coronary arteries [12].

Core Viewpoint - Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants to raise between $12 million and $15 million for regulatory clearance and market release of its Novasight Hybrid system, along with working capital needs [2][3]. Offering Details - The offering consists of a minimum of 26,666,667 and a maximum of 33,333,333 securities priced at $0.45 per common share or $0.44999 per pre-funded warrant [2]. - Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.00001, with no expiration and can be exercised on a cashless basis [2]. Use of Proceeds - The net proceeds from the offering will be used to obtain US FDA 510(k) clearance for the Novasight Hybrid system and to support a targeted market release in the United States, as well as for working capital and general corporate purposes [3]. Regulatory and Closing Information - The offering is expected to close on or about January 13, 2026, subject to customary closing conditions and necessary regulatory approvals [6]. - An amended and restated final short form prospectus was filed on January 7, 2026, which must be approved before any sale of securities [5]. Agent Compensation - The company will pay the agent a cash fee of 6.5% of the gross proceeds and grant compensation options equal to 6.5% of the total number of securities issued [7]. - A reduced cash commission of 3.25% will apply for certain purchasers on a president's list, with no compensation options for those sales [7]. Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid system being the first to combine intravascular ultrasound and optical coherence tomography [12].

Core Viewpoint - Bright Minds Biosciences Inc. has announced a public offering of 1,945,000 common shares at a price of $90.00 per share, aiming for gross proceeds of $175,050,000 to fund clinical trials and research initiatives [1][3]. Group 1: Offering Details - The public offering consists of 1,945,000 common shares priced at $90.00 each, with expected gross proceeds of $175,050,000 [1]. - The underwriters have a 30-day option to purchase an additional 291,750 common shares at the public offering price [1]. - The closing of the offering is anticipated on January 9, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund future clinical trials for drug candidates targeting absence seizures, developmental and epileptic encephalopathies (DEE), and Prader-Willi Syndrome [3]. - The funds will also support the initiation of phase 1 clinical trials for BMB-105 and additional research and development for earlier phase programs, along with general corporate and working capital purposes [3]. Group 3: Regulatory and Compliance - The company has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC), which became effective on September 2, 2025 [4]. - The offering is being conducted solely through a prospectus and a prospectus supplement that are part of the registration statement [4]. Group 4: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key brain receptors [7]. - The company aims to deliver breakthrough therapies for conditions with high unmet medical needs, including epilepsy and depression [7][8].

Core Viewpoint - Phathom Pharmaceuticals, Inc. plans to conduct an underwritten public offering of its common stock or pre-funded warrants, with a potential additional 15% option for underwriters [1][2] Group 1: Offering Details - The company intends to offer shares of its common stock or pre-funded warrants to certain investors [1] - The offering is subject to market conditions and other factors, with no assurance on completion or terms [1] - A shelf registration statement was filed with the SEC on January 7, 2026, which became effective automatically [3] Group 2: Use of Proceeds - Net proceeds from the offering will be used for general corporate purposes, including working capital and R&D expenses [2] Group 3: Company Background - Phathom Pharmaceuticals focuses on developing and commercializing treatments for gastrointestinal diseases [5] - The company has exclusive rights to vonoprazan, a potassium-competitive acid blocker, in the U.S., Europe, and Canada [5] - Vonoprazan is marketed in the U.S. for various gastrointestinal conditions, including heartburn and H. pylori infection [5]

Core Viewpoint - Mobix Labs (MOBX) has announced a public offering of 30,000,000 shares of its common stock, aiming for gross proceeds of approximately $6 million, which will be used for working capital and corporate purposes, including growth initiatives and M&A strategy [1] Group 1 - The public offering is expected to close on January 7, 2026, pending customary closing conditions [1] - D. Boral Capital is serving as the Sole Placement Agent for this offering [1] - The net proceeds from the offering will support the company's expansion in military, defense, aerospace, and connectivity markets [1]